Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

PURPOSE: Neoadjuvant anti–PD-1 therapy has shown promise for resectable non–small cell lung cancer (NSCLC). We reported the first phase I/II trial of neoadjuvant nivolumab in resectable NSCLC, finding it to be safe and feasible with encouraging major pathological responses (MPR). We now present 5-ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosner, Samuel, Reuss, Joshua E., Zahurak, Marianna, Zhang, Jiajia, Zeng, Zhen, Taube, Janis, Anagnostou, Valsamo, Smith, Kellie N., Riemer, Joanne, Illei, Peter B., Broderick, Stephen R., Jones, David R., Topalian, Suzanne L., Pardoll, Drew M., Brahmer, Julie R., Chaft, Jamie E., Forde, Patrick M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932577/
https://www.ncbi.nlm.nih.gov/pubmed/36794455
http://dx.doi.org/10.1158/1078-0432.CCR-22-2994